MediWound Ltd. operates in the specialized burn and wound treatment sector with its flagship product Nexobrid, supported by robust government contracts and key partnerships. Despite a 16% revenue decline in 2025, the company has invested heavily in expanding manufacturing capacity via a new GMP-compliant facility and sustained growth in R&D expenses, particularly for its diabetic foot ulcer product EscharEx. Persistent net losses highlight operational challenges amid high execution costs, while government funding through BARDA and MTEC remains crucial. The company's liquidity profile shows a healthy current ratio with active equity raises backing its strategy, but customer concentration and regulatory uncertainties suggest ongoing risk factors.